CCND1 and cancer: Research priorities have shifted from topics such as “radiation, RANKL, cyclin D1, RNA interference, and matrix metalloproteinase” to encompass areas such as “chemoresistance due to cisplatin, other therapeutic agents (metformin and monoclonal antibody), autophagy, inflammation, microRNA, cancer-associated fibroblasts, and STAT3 (with roles in cell migration and tumorigenesis).” These seven significant future research areas hold promise in identifying reliable biological markers for oral cancer detection and treatment, thereby improving clinical outcomes.